Phreesia (NYSE:PHR) Posts Earnings Results

Phreesia (NYSE:PHR) issued its quarterly earnings results on Monday. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11, Zacks reports. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%.

Phreesia Trading Down 0.0%

NYSE PHR traded down $0.01 on Monday, hitting $20.28. 3,640,192 shares of the company were exchanged, compared to its average volume of 631,028. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12. Phreesia has a twelve month low of $18.55 and a twelve month high of $32.76. The firm has a market capitalization of $1.21 billion, a P/E ratio of -48.28 and a beta of 0.64. The company’s 50 day moving average price is $22.09 and its 200-day moving average price is $25.28.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PHR shares. Citigroup restated an “outperform” rating on shares of Phreesia in a research report on Monday, September 8th. Stephens reaffirmed an “overweight” rating and set a $32.00 target price on shares of Phreesia in a research note on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a report on Friday, October 31st. Piper Sandler upped their price target on shares of Phreesia from $33.00 to $34.00 and gave the company an “overweight” rating in a report on Friday, September 5th. Finally, Canaccord Genuity Group lifted their price objective on shares of Phreesia from $34.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. Fourteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.86.

Insiders Place Their Bets

In other Phreesia news, insider David Linetsky sold 2,165 shares of Phreesia stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $50,401.20. Following the transaction, the insider owned 174,952 shares of the company’s stock, valued at $4,072,882.56. The trade was a 1.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Allison C. Hoffman sold 3,133 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $72,936.24. Following the completion of the sale, the general counsel directly owned 139,037 shares of the company’s stock, valued at $3,236,781.36. This trade represents a 2.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 26,174 shares of company stock valued at $603,835 over the last 90 days. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Phreesia

Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in shares of Phreesia by 332.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company’s stock worth $160,000 after purchasing an additional 4,313 shares during the period. Creative Planning acquired a new stake in Phreesia in the 3rd quarter valued at approximately $218,000. Globeflex Capital L P grew its holdings in Phreesia by 62.3% in the 2nd quarter. Globeflex Capital L P now owns 10,070 shares of the company’s stock valued at $287,000 after buying an additional 3,866 shares during the last quarter. Prudential Financial Inc. bought a new position in Phreesia in the 2nd quarter worth approximately $298,000. Finally, Caxton Associates LLP acquired a new position in shares of Phreesia during the first quarter worth approximately $316,000. 92.10% of the stock is owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.